Drugs / alendronate/cholecalciferol
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00593580 Comparator | Feb 2008 → Jun 2011 | ovarian cancer | British Columbia Cancer Agency | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | alendronate/cholecalciferol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00593580 ↗ |
| Route | Oral | “weekly oral FOSAVANCE 70 mg alendronate/2800 IU cholecalciferol or placebo for the 12 months of the study duration” NCT00593580 ↗ |